Lumida
/JYNT
⌘K
Joint Corp

Joint Corp

JYNT
$7.85USD-2.24%-0.18 today

MARKET CAP

111.0M

P/E (TTM)

34.1x

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$8
$11

AI Summary

Stalk
Buy NowMedium

JYNT is in Stage 2 advancing, having built a clear higher‐highs/higher‐lows sequence off its May lows and trading above rising 9/21/50 EMAs on expanding volume. Active Lockout Rally and HH/HL patterns reinforce bullish continuation, while short‐term pullbacks into the EMAs are supported. Despite overbought signals and a declining 200 DMA overhead, timing conditions favor immediate participation to ride further upside momentum.

  • Cash flow from operations jumped 152% YoY to $2.2M
  • Re-franchising reduces company-owned clinics to three, lowering capital needs
  • Same-store sales fell 2.8% in Q2, indicating demand headwinds
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$80.0M$101.3M$47.0M$52.2M$54.9M
YoY %+36.3%+26.5%-53.6%+11.0%+5.2%
P / Sales12.3x2.0x3.0x3.1x2.4x
EV / Sales12.7x2.5x3.9x3.8x2.8x
Gross Profit, Adj.$72.3M$92.1M$36.5M$40.6M$43.7M
YoY %+38.7%+27.3%-60.4%+11.4%+7.4%
Margin %90.4%90.9%77.7%77.9%79.6%
EV / Gross Profit14.1x2.8x5.1x4.9x3.5x
EBITDA, Adj.$10.1M$7.9M$8.9M$2.9M$808,241
YoY %+23.2%-21.7%+12.6%-67.4%-72.1%
Margin %12.6%7.8%18.9%5.6%1.5%
EV / EBITDA101.1x32.5x20.9x68.4x191.4x
EBIT$6.2M$1.2M$297,405$-1.8M$-905,478
YoY %+13.1%-79.9%-76.0%-713.0%+50.3%
Margin %7.7%1.2%0.6%-3.5%-1.6%
EV / EBIT165.5x206.6x623.5x-108.9x-170.9x
Net Income$7.6M$626,705$-9.8M$-5.8M$2.9M
YoY %-42.5%-91.7%-1656.1%+40.6%+150.2%
Net Margin9.5%0.6%-20.8%-11.1%5.3%
EPS (GAAP)$0.51$0.04-$0.65-$0.38$0.19
YoY %-43.3%-92.2%-1725.0%+41.5%+150.0%